Showing results (141-150 of 494) with videos related to
Sort By:
Pageof 50
Journal of Health Politics, Policy and Law|May 21, 2014
Life cycle of medical product rules issued by the US Food and Drug AdministrationThomas J Hwang, Jerry Avorn, Aaron S KesselheimJournal of Managed Care & Specialty Pharmacy|October 31, 2025
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiationJohn Kim, Aaron S Kesselheim, Benjamin N RomeThe Lancet. Microbe|June 17, 2024
Implementing an EU pull incentive for antimicrobial innovation and access: blueprint for actionMichael Anderson, Adrian Towse, Kevin Outterson, et al.Nature Reviews. Microbiology|November 21, 2019
The global preclinical antibacterial pipelineUrsula Theuretzbacher, Kevin Outterson, Aleks Engel, et al.The Lancet. Infectious Diseases|July 25, 2007
Will longer antimicrobial patents improve global public health?Kevin Outterson, Julie Balch Samora, Karen Keller-CudaHealth Affairs (Project Hope)|May 3, 2021
Frequency Of Generic Drug Price Spikes And Impact On Medicaid SpendingAayan N Patel, Aaron S Kesselheim, Benjamin N RomeNeurology|September 8, 2021
Discovery and Development of Pregabalin (Lyrica): The Role of Public FundingRachel Barenie, Jonathan Darrow, Jerry Avorn, et al.JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S KesselheimJournal of Health Politics, Policy and Law|March 30, 2023
Trust and Regulation: Assuring Scientific Independence in the FDA's Emergency Use Authorization ProcessNeeraj G Patel, Aaron S Kesselheim, Jonathan J DarrowClinical Pharmacology and Therapeutics|July 13, 2020
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018Benjamin N Rome, ChangWon C Lee, Aaron S KesselheimPageof 50